Who May Be a Candidate for HIPEC? Peritoneal Spread, Imaging and the Surgical Evaluation

The scan report arrives before the appointment does. Somewhere in the second paragraph sits a phrase nobody explained: “peritoneal nodularity.” A search engine fills in the rest, and by evening a person who felt reasonably well at breakfast is reading about cytoreductive surgery, heated chemotherapy and a procedure with an acronym that sounds like a piece of lab equipment.

Whether someone is a HIPEC candidate with peritoneal spread is one of the harder questions in cancer surgery, and it is rarely answered by a single test. Surgeons weigh where the cancer started, how much of the abdominal lining it has reached, what the imaging can and cannot show, and how much surgery a body can safely absorb.

This explainer walks through that evaluation the way a peritoneal surface team actually approaches it: not as a verdict, but as a series of questions, some of which only an operation can answer.

What does "peritoneal spread" actually mean?

Picture the inside of the abdomen as a room lined with a thin, glistening wallpaper. That lining is the peritoneum, a membrane that covers the inner wall of the belly and wraps the organs inside it. When cancer cells break free from a primary tumor and settle on this surface, doctors call it peritoneal spread, peritoneal metastasis or, when the deposits are numerous, peritoneal carcinomatosis.

The distinction from other kinds of metastasis matters. Cancer that travels through the bloodstream to the liver or lungs is a systemic problem from the first day. Cancer that seeds the peritoneum often spreads by direct contact: a tumor on the surface of the colon, stomach, ovary or appendix sheds cells into the abdominal cavity, and those cells drift and attach where fluid pools. For a period, the disease may be regional rather than truly everywhere. That window of regional disease is the entire premise behind treating the peritoneum as a surgical target.

Not every peritoneal deposit behaves the same way. Cleveland Clinic notes that peritoneal carcinomatosis most often arises from cancers of the digestive tract and gynecologic organs, and that the primary site strongly shapes how it behaves and how it is treated. A slow-growing mucus-producing appendix tumor may coat the abdomen for years without invading deeply. An aggressive gastric cancer can seed widely within months. Same wallpaper, very different stains.

Symptoms, when they appear, tend to be nonspecific: bloating, a change in appetite, fluid buildup called ascites, or a bowel that does not move as it should. Often, though, peritoneal spread is found on a scan ordered for another reason or during surgery for the primary tumor, which is why the conversation so frequently begins with a report rather than a feeling.

Is HIPEC a treatment for peritoneal cancer, and what does cytoreductive surgery and HIPEC involve?

HIPEC stands for hyperthermic intraperitoneal chemotherapy: chemotherapy drugs, warmed above body temperature, circulated directly inside the abdominal cavity during surgery. Yes, it is a treatment used for certain cancers that have spread to the peritoneum. But HIPEC almost never travels alone, and understanding that is the first correction most people need.

The larger part of the treatment is cytoreductive surgery, usually abbreviated CRS. Cytoreduction simply means reducing the amount of cancer. In practice it means a surgeon opens the abdomen and systematically removes every visible tumor deposit: stripping affected sections of peritoneum, removing involved organs or parts of organs, sometimes taking the omentum (the fatty apron that hangs over the intestines) and the spleen or gallbladder if they carry disease. Johns Hopkins describes the combined operation as one that can last many hours, frequently well beyond eight, precisely because the surgeon is working across the entire cavity rather than at one site.

Only after that removal does HIPEC begin. The logic is sequential. Surgery handles what the eye can see; heated chemotherapy is aimed at microscopic cells left behind on raw surfaces where no scalpel can reach. Delivering the drug straight into the cavity exposes those surfaces to concentrations that would be intolerable if the same drug circulated through the whole body, while comparatively little is absorbed into the bloodstream.

So the honest framing is this: a person is evaluated as a candidate for cytoreductive surgery first. HIPEC is the second act, and whether it is added depends on the cancer type, the completeness of the surgery and the evidence for that particular disease, which is far stronger for some tumors than for others.

How HIPEC works, step by step, in plain language

Once the surgeon has removed everything visible, the operating team sets up a closed circuit. Tubes are placed into the abdomen and connected to a perfusion machine, a pump and heater that warms the chemotherapy solution and circulates it through the cavity. Cleveland Clinic describes the fluid being heated to roughly 41 to 43 degrees Celsius, about 106 to 109 degrees Fahrenheit, a few degrees above normal body temperature.

Heat does two useful things. Cancer cells tolerate heat less well than healthy tissue, and warmth makes several chemotherapy drugs penetrate tissue more deeply and act more forcefully. The exposure is brief compared with standard chemotherapy: the PRODIGE 7 trial used a 30-minute perfusion with an oxaliplatin-based solution, while the OVHIPEC trial in ovarian cancer circulated a cisplatin-based solution for 90 minutes. Drug choice, concentration and timing are decisions for the surgical and oncology team and vary by cancer type; nothing about them is standardized across all diseases.

During perfusion the abdomen is gently agitated, either by the surgeon’s hands through a temporary covering or by rocking the patient, so the solution reaches every fold and crevice. Temperature probes monitor the cavity to keep the fluid in range. When the timed perfusion ends, the solution is drained, the cavity is rinsed, and the surgeon completes any reconstruction, such as rejoining bowel, before closing.

Two features of this design explain both its appeal and its limits. Because the drug bathes surfaces rather than penetrating deep tissue, HIPEC is meant for residual deposits measured in millimeters, not centimeters. That is why the completeness of the surgery beforehand is not a detail. It is the whole point.

Who may be a HIPEC candidate with peritoneal spread? Start with the primary tumor

Ask a peritoneal surface surgeon the first thing they want to know about a referral, and the answer is rarely the size of the tumor burden. It is where the cancer came from. The biology of the primary tumor sets the ceiling on what any surgery can achieve.

Candidacy tends to be considered most readily for a handful of diagnoses. Pseudomyxoma peritonei, a rare condition in which a ruptured appendix tumor fills the abdomen with jelly-like mucin, is the classic case: the disease spreads along surfaces, seldom travels through the bloodstream, and Cleveland Clinic and Johns Hopkins both list it among the conditions for which cytoreductive surgery with HIPEC is an established approach. Peritoneal mesothelioma, a cancer of the lining itself, is another. Colorectal cancer with limited peritoneal spread and no disease elsewhere is frequently evaluated, though, as a later section explains, the evidence specifically for the heated chemotherapy component in colorectal cancer has become more nuanced. Selected people with ovarian cancer are considered in specific settings, and some centers evaluate gastric cancer within research protocols.

Equally important is what the primary tumor is doing elsewhere. Cytoreductive surgery treats the peritoneum; it does nothing for cancer already in the liver, lungs or bones. Widespread systemic disease generally places someone outside the candidate pool, because a demanding operation on one compartment cannot control disease in others. Some teams do consider a small number of liver deposits alongside peritoneal disease, but that is a case-by-case discussion, not a rule.

Where the cancer started, how it has behaved on prior treatment and whether it has stayed regional together answer the first question. Only then does the conversation move to how much disease sits on the lining.

The peritoneal cancer index score: why one number shapes so much

Surgeons needed a shared language for “how much cancer is on the peritoneum,” and the peritoneal cancer index, usually shortened to PCI, is that language. The abdomen is divided into 13 regions: nine across the belly like a tic-tac-toe grid, plus four segments of the small intestine. Each region is scored from 0, meaning no tumor, to 3, meaning deposits larger than about five centimeters or confluent sheets of tumor. The regional scores are added together, so the index runs from 0 to 39.

The number matters for two reasons. A higher PCI means more surfaces to strip and more organs likely to be involved, which lengthens the operation and raises the chance of complications. It also correlates, in most studies of most tumor types, with how likely the surgeon is to achieve complete cytoreduction. Trials have used the index as an entry gate: PRODIGE 7, the largest randomized study of HIPEC in colorectal peritoneal metastasis, enrolled people with a PCI of 25 or less. Programs treating pseudomyxoma peritonei often accept much higher indices because that disease sits on surfaces rather than invading them, which is one more reminder that the number is interpreted through the lens of the primary tumor.

A second score is recorded at the end of surgery: the completeness of cytoreduction score, or CC score. CC-0 means no visible disease remains; CC-1 means only deposits smaller than a couple of millimeters, the size range HIPEC is designed to reach. CC-2 and CC-3 mean larger residual tumor, and in that situation the heated chemotherapy adds risk without a realistic mechanism of benefit.

The candid reality is that the PCI cannot be measured precisely from outside the body. Imaging estimates it. Only the operation confirms it.

What imaging can show about peritoneal disease, and what it routinely misses

A CT scan of the abdomen and pelvis with contrast is the workhorse of the evaluation. It maps the primary tumor, checks the liver and lungs for spread, shows fluid, and reveals larger peritoneal deposits, thickening of the omentum and bowel that looks tethered or obstructed. It is fast, widely available and reasonably good at answering the question that excludes people quickly: is there disease outside the abdomen?

Where CT struggles is at the small end. Peritoneal deposits often measure a few millimeters, sit flat against surfaces, and share density with the bowel and fat around them. Cleveland Clinic and Johns Hopkins both acknowledge that scans tend to underestimate the true extent of peritoneal carcinomatosis, particularly on the small intestine, which is precisely the region that most often decides whether complete removal is possible. A small bowel coated in fine deposits may look nearly normal on a scan and prove unresectable in the operating room.

Other tools fill gaps rather than replace CT. MRI with diffusion-weighted sequences, which highlights tissue where water moves less freely, can sharpen detection of small deposits and is used in some programs, especially for mucinous disease. PET-CT, which tracks sugar uptake, helps identify distant metastases and is more useful for tumors that take up the tracer avidly; it is unreliable for mucin-rich, low-cellularity tumors, which may barely light up at all.

Blood tests round out the picture. Tumor markers such as CEA, CA-125 or CA 19-9, depending on the primary, are followed over time as one indicator of disease activity. None of these tests, alone or together, delivers a candidacy decision. What they deliver is a probability estimate that the surgeon then decides whether to test directly.

Diagnostic laparoscopy and the fitness assessment: the two tests that decide most cases

When imaging leaves the question open, many teams propose a diagnostic laparoscopy: a short operation under general anesthesia in which a camera is passed through one or two small incisions so the surgeon can look directly at the peritoneal surfaces. Laparoscopy allows the surgeon to estimate the PCI with far more confidence than a scan, inspect the small bowel and its mesentery, take biopsies to confirm the diagnosis and tumor type, and judge whether a complete cytoreduction looks achievable. It also carries risks of its own and is not always feasible after multiple prior operations.

The other half of the evaluation has nothing to do with the tumor. Cytoreductive surgery with HIPEC is among the most physiologically demanding operations in cancer care. Teams assess heart and lung function, kidney function, liver function and blood counts. They look closely at nutrition, because people with peritoneal disease often arrive having lost weight and muscle, and poor nutrition predicts slower healing and more complications. Functional status, meaning how much of ordinary daily life a person can manage independently, is weighed heavily; formal scales exist, but the underlying question is whether the body has reserve to spend.

Age by itself is not a cutoff. Fitness is. An active older adult with good organ function may be a stronger candidate than a younger person whose kidneys or heart are already strained.

Prior chemotherapy also enters the calculation, sometimes in a person’s favor. Disease that stays stable or shrinks on systemic treatment demonstrates the kind of biology surgery can build on. Disease that grows through chemotherapy suggests an aggressiveness that a regional operation is unlikely to hold back, and most teams regard that as a signal to pause.

HIPEC candidate or not: peritoneal factors that favor surgery, and those that give pause

No two evaluations weigh these factors identically, and a feature in the “pause” column is rarely a permanent exclusion. Some people are asked to complete additional systemic chemotherapy and return for reassessment; others are found to be candidates only after a laparoscopy clears an uncertainty. The table below summarizes how peritoneal surface programs commonly describe the balance.

Factor	Tends to favor evaluation for CRS and HIPEC	Tends to prompt caution or a wait
Primary tumor	Pseudomyxoma peritonei, peritoneal mesothelioma, selected colorectal and ovarian cancers	Highly aggressive primaries or types without supporting evidence outside research protocols
Disease outside the peritoneum	None on imaging	Liver, lung, bone or distant lymph node metastases
Extent on the lining (PCI)	Limited, with surgeon confident of complete removal	Extensive disease, especially coating the small bowel or its mesentery
Response to prior chemotherapy	Stable or shrinking	Growing despite treatment
Overall fitness	Good organ function, adequate nutrition, independent daily living	Significant heart, lung or kidney disease; marked weight and muscle loss
Bowel function	Working normally	Obstruction at more than one level, or dependence on intravenous nutrition

Two entries deserve emphasis. Small bowel involvement is the quiet decider in many cases, because the intestine cannot be stripped like the abdominal wall; only limited lengths can be removed while preserving the ability to eat and absorb. And “wait” is a real category with a real purpose. A period of systemic treatment can reveal the tumor’s tempo, improve nutrition, and turn an uncertain candidate into a clearer one, or spare someone a major operation that would not have helped.

The decision is made by a multidisciplinary team, typically surgical oncology, medical oncology, radiology and pathology together, and it is revisited as new information arrives.

What the evidence says, tumor by tumor, without the sales pitch

Evidence for CRS and HIPEC is uneven, and an honest evaluation names the unevenness rather than smoothing it over.

For pseudomyxoma peritonei and peritoneal mesothelioma, randomized trials do not exist and are unlikely to be conducted, because the diseases are rare and alternatives are limited. Support rests on large observational series accumulated over decades, and both Cleveland Clinic and Johns Hopkins describe cytoreductive surgery with HIPEC as an established approach for these conditions. Observational evidence is graded lower than randomized evidence, but for these two diseases it is the best available and it has shaped practice worldwide.

Colorectal cancer is where the picture shifted. The PRODIGE 7 trial, published in The Lancet Oncology, randomized people with colorectal peritoneal metastases to cytoreductive surgery with or without oxaliplatin-based HIPEC. Adding the heated chemotherapy did not improve overall survival compared with complete surgery alone, and it increased late complications. What the trial did reinforce is that complete cytoreductive surgery itself, in well-selected people, was associated with meaningful survival in both arms. Many programs have since re-examined which drug, if any, to use for colorectal disease, and some offer surgery alone or enroll people in ongoing studies. A person evaluated today should expect that nuance to be discussed openly.

Ovarian cancer moved in the other direction. The OVHIPEC trial in The New England Journal of Medicine found that adding cisplatin-based HIPEC to interval cytoreductive surgery, performed after initial chemotherapy in stage III disease, was associated with longer recurrence-free and overall survival than surgery alone, without a rise in serious complications. Guidelines treat this as one option in that specific setting rather than a universal recommendation.

Gastric cancer remains largely investigational. Anyone offered HIPEC for gastric peritoneal disease should ask whether it is within a clinical trial.

Peritoneal carcinomatosis life expectancy: how to read prognosis numbers honestly

Two questions come up in almost every consultation, sometimes whispered: what is the life expectancy with peritoneal carcinomatosis, and what is it after HIPEC? The most truthful response is that there is no single figure, and any source offering one without qualification is not describing your situation.

Prognosis with peritoneal spread depends first on the primary tumor. Slow-growing mucinous appendix disease and aggressive gastric cancer can both be labeled “peritoneal carcinomatosis” and occupy opposite ends of the outlook spectrum. Within a single tumor type, the extent of disease, whether complete cytoreduction is achievable, how the cancer responded to systemic therapy, the person’s fitness and the tumor’s molecular features all shift the estimate.

Published survival statistics carry their own caveats. Figures from surgical series describe people who were selected as candidates, which means they were healthier and had less disease than the average person with the diagnosis; that selection alone makes outcomes look better than the treatment can claim credit for. Trial figures describe narrowly defined groups treated under protocol. Historical numbers lag current practice by years. None of them knows your scan.

What a person can reasonably ask is for their own team to describe a range: what similar people in their program have experienced, what factors in their case pull toward the better or worse end, and how much uncertainty surrounds the estimate. Oncologists are trained to give this kind of answer, and most will, if asked directly.

Life expectancy is also not the only outcome that matters. Time free of bowel obstruction, time without fluid needing drainage, and time feeling well enough to live ordinarily are outcomes surgery is sometimes chosen for even when the survival gain is uncertain. Saying so out loud tends to make the conversation more useful, not more frightening.

HIPEC surgery recovery time: what the following days and weeks usually look like

The operation ends; the work does not. Most people wake in an intensive care or high-dependency unit, with a breathing tube already removed or removed within a day, a urinary catheter, drains from the abdomen, intravenous lines and, often, an epidural or patient-controlled pump for pain. How painful is HIPEC surgery? The incision runs the length of the abdomen and internal surfaces have been stripped, so discomfort is significant in the first days. Modern pain protocols combine regional anesthesia with scheduled medications and aim for pain controlled enough to breathe deeply, cough and move, which are the activities that prevent pneumonia and clots. The care team adjusts the plan daily.

The bowel is slow to restart after this much handling and heat. Eating begins with sips and progresses over days; some people need intravenous nutrition for a period. Fatigue is profound and expected. Blood counts and kidney function are checked frequently, because the chemotherapy exposure, though localized, can affect both.

Hospital stays vary widely with the extent of surgery. Johns Hopkins describes a typical stay in the range of one to two weeks, with longer stays when complications arise. Cleveland Clinic describes full recovery, meaning a return to usual energy and eating, as commonly taking around two to three months, and longer for some.

The weeks at home follow a familiar rhythm: walking a little more each day, small frequent meals, gradual weaning from pain medication, and watching the incision. Weight often continues to drift down before it stabilizes. Follow-up imaging and tumor markers begin in the months after surgery and continue for years, because the goal of surveillance is to catch recurrence while it is still regional.

These are typical ranges, not promises. A person’s own course depends on what was removed and how their body responds.

Risks and alternatives, described the way a surgeon should describe them

Any evaluation that does not spend real time on risk is incomplete. Cytoreductive surgery with HIPEC carries the general risks of major abdominal surgery, amplified by its length and scope: bleeding, infection, blood clots in the legs or lungs, pneumonia and reactions to anesthesia. Its specific risks follow from what is done. Where bowel is rejoined, the connection can leak, which is among the most serious complications and may require further surgery or a temporary stoma, an opening on the abdominal wall that diverts stool into a bag. Where the pancreas is disturbed, digestive fluid can leak. Where large surfaces are stripped, fluid and protein losses can be substantial.

The chemotherapy adds its own concerns despite limited absorption: temporary suppression of blood counts, kidney strain, and in the PRODIGE 7 trial a higher rate of late complications in the HIPEC group compared with surgery alone. Mortality related to the operation exists and is discussed candidly at experienced programs; it is one reason fitness is weighed so heavily.

Alternatives depend on the disease. Systemic chemotherapy, sometimes with targeted or immune-based drugs chosen by tumor type and molecular features, remains the standard for many people with peritoneal spread and may be the better choice when disease is extensive or aggressive. Surgery without HIPEC is now a considered option for some colorectal cases. Less extensive procedures can relieve specific problems such as obstruction or fluid buildup without attempting complete removal. Clinical trials, including newer approaches to delivering drugs into the abdomen, are open for several tumor types. And supportive care focused on symptoms and quality of life is a legitimate, active choice rather than an absence of treatment.

Which path fits is a decision the treating team makes with the person, weighing their goals as seriously as their scans.

What people often get wrong about HIPEC candidacy

The first misunderstanding is that HIPEC is the treatment. It is not. The surgery is the treatment; the heated chemotherapy is an adjunct, and its value depends entirely on the surgery leaving almost nothing behind. Someone told they are “not a candidate for HIPEC” is almost always being told that complete cytoreduction is not achievable or not safe, which is a different and more specific message.

The second is that a clean scan means a small tumor burden. Imaging underestimates peritoneal disease, as both Cleveland Clinic and Johns Hopkins acknowledge, which is why laparoscopy exists and why some operations are stopped after the surgeon looks inside. A person can be a reasonable candidate on paper and not one in the operating room; that outcome reflects the limits of imaging, not a failure of anyone involved.

The third is that a “no” today is a “no” forever. Teams frequently recommend systemic chemotherapy first and reassess. Disease that responds, nutrition that improves, or a fuller picture from repeat imaging can change the answer.

The fourth is that heat is the active ingredient and any chemotherapy will do. The evidence is drug- and disease-specific. PRODIGE 7 showed that one drug regimen added nothing measurable for colorectal disease; OVHIPEC showed a different regimen in a different cancer was associated with benefit. Neither result transfers automatically.

The fifth is that HIPEC belongs to a country or a single famous center. Peritoneal surface programs exist in many health systems, and what predicts a careful evaluation is experience with the disease and a genuine multidisciplinary process, not geography or marketing.

The last is subtler: that declining surgery means giving up. People weigh a long recovery against uncertain gain and choose systemic treatment or symptom-focused care for sound reasons. That is a decision, not a surrender.

Questions to ask your care team before deciding

A consultation about cytoreductive surgery and HIPEC moves quickly and covers a great deal. Writing questions down beforehand, and bringing someone to take notes, changes how much a person walks away with. The questions below are the ones peritoneal surface teams tend to welcome, because they show the person understands what is actually being decided.

• Based on my primary tumor type, what does the evidence say about cytoreductive surgery, and separately about adding HIPEC?
• What is your estimate of my peritoneal cancer index from imaging, and how confident are you in it?
• Would a diagnostic laparoscopy change the plan, and what would you be looking for?
• How likely is it that you can achieve complete cytoreduction, and what would make you stop during the operation?
• Which organs or sections of bowel might need to be removed, and could I need a temporary or permanent stoma?
• What are the most serious complications you see, and how often do they require another operation?
• Would systemic chemotherapy before surgery help clarify whether I am a candidate?
• If I am not a candidate now, what would need to change for me to be reconsidered?
• How many of these operations does your program perform, and is the decision made in a multidisciplinary meeting?
• Is there a clinical trial I should know about, here or elsewhere?
• What does recovery typically look like for someone with my extent of disease, and what support is available at home?
• If I choose not to have surgery, what are the alternatives, and how would we manage symptoms?

One more question is worth asking of oneself as much as the team: what am I hoping this operation will give me? Time, relief from a specific symptom, or the sense of having tried everything are all legitimate answers, and naming the goal helps the team judge whether the operation can serve it.

When to call your doctor: red-flag signs before and after HIPEC

Peritoneal disease can change quickly, and so can recovery from major surgery. Whether someone is waiting for an evaluation, partway through preoperative chemotherapy or weeks past the operation, certain signs warrant a same-day call to the treating team rather than a wait for the next scheduled visit.

Before surgery, contact the team promptly for persistent vomiting or inability to keep fluids down, a belly that is rapidly swelling or becoming tight and painful, no bowel movement or gas passing for more than a day or two alongside cramping, new shortness of breath, or fever during chemotherapy. These can signal bowel obstruction, rapidly accumulating fluid, infection or a clot, each of which changes the timeline.

After surgery, the red flags that surgical teams ask people to report without delay include fever or shaking chills; wound redness spreading outward, opening, or leaking cloudy or foul-smelling fluid; abdominal pain that is worsening rather than easing, or a belly that becomes hard and distended; repeated vomiting or an inability to tolerate food after having been eating; a stoma that turns dark or stops producing output; calf pain or swelling on one side; sudden breathlessness or chest pain; dizziness or fainting; and little or no urine over several hours. Any of these may indicate a leak, infection, obstruction, clot or kidney strain, and all are more manageable when caught early.

Seek emergency care immediately for severe chest pain, difficulty breathing, heavy bleeding, confusion or collapse.

None of this replaces the specific instructions a surgical team gives at discharge, which take precedence. The broader principle is simple: after an operation of this scale, a change that feels wrong deserves a phone call, and clinicians would rather hear about a false alarm than learn about a real problem late.

Frequently asked questions

Is HIPEC a treatment for peritoneal cancer?

Yes, HIPEC is used to treat certain cancers that have spread to the peritoneum, but almost always as an addition to cytoreductive surgery rather than on its own. The surgery removes visible tumor; the heated chemotherapy targets microscopic cells left behind. Its role is best established for pseudomyxoma peritonei and peritoneal mesothelioma, is debated for colorectal cancer after the PRODIGE 7 trial, and is supported in one specific ovarian cancer setting by the OVHIPEC trial.

What is the life expectancy for someone with peritoneal carcinomatosis?

There is no single figure, because the outlook depends heavily on the primary tumor type, how much of the peritoneum is involved, whether disease exists elsewhere, how the cancer responds to systemic treatment and the person’s overall health. Slow-growing mucinous appendix tumors and aggressive gastric cancers sit at opposite ends of the range. Your own oncology team can describe a realistic range for your specific situation and explain which factors pull it in either direction.

What is the life expectancy after HIPEC surgery?

It varies by cancer type and by whether the surgeon achieved complete cytoreduction, and published figures describe carefully selected groups rather than everyone with the diagnosis. Selection itself makes outcomes look better than the treatment alone can claim. The most useful numbers come from your own team, who can tell you what people with similar disease and fitness have experienced in their program and how much uncertainty surrounds that estimate.

How painful is HIPEC surgery?

Significant discomfort in the first days is expected, because the incision runs the length of the abdomen and internal surfaces have been stripped. Teams typically combine an epidural or patient-controlled pump with scheduled medications, adjusting daily, with the goal of pain controlled well enough to breathe deeply and walk, which prevents pneumonia and clots. Pain generally eases over the first weeks, and most people wean off stronger medication during recovery at home.

What is the hipec surgery recovery time?

Johns Hopkins describes a typical hospital stay in the range of one to two weeks, longer if complications occur, and Cleveland Clinic describes a return to usual energy and eating as commonly taking around two to three months. Bowel function is slow to restart, fatigue is profound early on, and weight often drifts down before stabilizing. These are typical ranges tied to how much was removed, not guarantees, and your surgical team will set expectations for your case.

What is the peritoneal cancer index score and why does it matter?

The peritoneal cancer index, or PCI, divides the abdomen into 13 regions and scores each from 0 to 3 based on the largest tumor deposit, for a total of 0 to 39. Higher scores mean more surfaces and organs involved, a longer operation and a lower likelihood of complete removal. Trials have used it as an entry gate; PRODIGE 7 enrolled people with a PCI of 25 or less. It is estimated from imaging but only confirmed at surgery.

Can a CT scan tell if I am a candidate for cytoreductive surgery and HIPEC?

Only partly. CT is good at ruling out spread outside the abdomen and showing larger deposits, fluid and obstruction, but it routinely underestimates small peritoneal deposits, especially on the small bowel. That is why many teams add MRI, PET-CT or, most decisively, a diagnostic laparoscopy to look directly at the surfaces before committing to a long operation. Even then, some operations are stopped once the surgeon sees more disease than expected.

Who is usually asked to wait before being considered for HIPEC?

People whose disease is growing despite chemotherapy, who have cancer outside the peritoneum, whose small bowel is extensively involved, or whose nutrition, heart, lung or kidney function is not yet strong enough for a long operation are often asked to complete systemic treatment and return for reassessment. A wait is not a permanent no; improved nutrition, a good response to chemotherapy or clearer imaging can change the answer at a later multidisciplinary review.

Does the evidence for HIPEC differ by cancer type?

Substantially. For pseudomyxoma peritonei and peritoneal mesothelioma, support comes from long observational experience rather than randomized trials. For colorectal cancer, the PRODIGE 7 randomized trial found that adding oxaliplatin-based HIPEC to complete surgery did not improve overall survival. For stage III ovarian cancer, the OVHIPEC trial found cisplatin-based HIPEC with interval surgery was associated with longer survival. Gastric cancer remains largely investigational, ideally within a clinical trial.

Does age rule someone out as a HIPEC candidate?

Age alone is not a cutoff; fitness is what teams assess. Heart, lung, kidney and liver function, nutritional status and how independently a person manages daily life carry far more weight than the number of birthdays. An active older adult with good organ function may be a stronger candidate than a younger person with significant medical problems. The evaluation is individual and rests with the multidisciplinary team.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.